Accession Number : ADA599938


Title :   Clinical Trial of AC105 (Mg/PEG) for Treatment of Acute Spinal Cord Injury (SCI). Phase 2


Descriptive Note : Annual rept. 30 Sep 2012-29 Sep 2013


Corporate Author : ACORDA THERAPEUTICS INC HAWTHORNE NY


Personal Author(s) : Blight, Andrew


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a599938.pdf


Report Date : Oct 2013


Pagination or Media Count : 11


Abstract : Acorda Therapeutics, Inc. is developing the polymer formulation of magnesium, known as AC-105, for the treatment of acute spinal cord injury. This trial is partially supported by the funds from this Department of Defense Broad Agency Announcement for Extramural Medical Research grant. The primary hypothesis of this proposed study is that treatment of people with acute SCI with AC-105 will result in greater normalization of CNS Mg than treatment with MgCl2 or saline solutions and potentially improve neurological outcome from injury.


Descriptors :   *CENTRAL NERVOUS SYSTEM , *CLINICAL TRIALS , *SPINAL CORD , *WOUNDS AND INJURIES , FORMULATIONS , MAGNESIUM , MEDICAL RESEARCH , MEDICINE , NEUROLOGY , NORMALIZING(STATISTICS) , POLYMERS , SPINAL COLUMN


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE